Cargando…
ACE2 Elevation in Severe COVID-19
Autores principales: | Reindl-Schwaighofer, Roman, Hödlmoser, Sebastian, Eskandary, Farsad, Poglitsch, Marko, Bonderman, Diana, Strassl, Robert, Aberle, Judith H., Oberbauer, Rainer, Zoufaly, Alexander, Hecking, Manfred |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Thoracic Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314901/ https://www.ncbi.nlm.nih.gov/pubmed/33600742 http://dx.doi.org/10.1164/rccm.202101-0142LE |
Ejemplares similares
-
The systemic renin-angiotensin system in COVID-19
por: Reindl-Schwaighofer, Roman, et al.
Publicado: (2022) -
Corticosteroid Treatment Prevents Lipopolysaccharide-Induced Increase of ACE2 and Reduces Fibrin Degradation Products in Bronchoalveolar Lavage Fluid
por: Reindl-Schwaighofer, Roman, et al.
Publicado: (2022) -
Renin-angiotensin system inhibitor discontinuation in COVID-19 did not modify systemic ACE2 in a randomized controlled trial
por: Rathkolb, Vincent, et al.
Publicado: (2023) -
The Effect of FGF23 on Cardiac Hypertrophy Is Not Mediated by Systemic Renin-Angiotensin- Aldosterone System in Hemodialysis
por: Dörr, Katharina, et al.
Publicado: (2022) -
Bone Specific Alkaline Phosphatase and Serum Calcification Propensity Are Not Influenced by Etelcalcetide vs. Alfacalcidol Treatment, and Only Bone Specific Alkaline Phosphatase Is Correlated With Fibroblast Growth Factor 23: Sub-Analysis Results of the ETACAR-HD Study
por: Dörr, Katharina, et al.
Publicado: (2022)